Get the Stockscreener App
42.23
1.00%
-0.225
Soleno Therapeutics Inc stock is traded at $42.23, with a volume of 778.71K.
It is down -1.00% in the last 24 hours and down -15.85% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$42.46
Open:
$42.27
24h Volume:
778.71K
Relative Volume:
0.44
Market Cap:
$2.27B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-14.09
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
-7.62%
1M Performance:
-15.85%
6M Performance:
-49.71%
1Y Performance:
-13.46%
1-Day Range:
$41.50
$42.99
1-Week Range:
$39.43
$45.88
52-Week Range:
$39.43
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
42.26 | 2.28B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.07 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.33 | 79.26B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
807.75 | 49.47B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.54 | 48.47B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.57 | 38.37B | 4.98B | 69.59M | 525.67M | 0.5197 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-07-25 | Initiated | Goldman | Buy |
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Q4 EPS Estimate for Soleno Therapeutics Increased by Analyst - MarketBeat
Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Finviz
Soleno Therapeutics: Why I’m Staying On The Sidelines (NASDAQ:SLNO) - Seeking Alpha
Jobs Data: Is Soleno Therapeutics Inc in a bullish channel2025 Earnings Impact & Trade Opportunity Analysis - baoquankhu1.vn
Relative Strength Alert For Soleno Therapeutics - Nasdaq
Cantor Fitzgerald reiterates Overweight rating on Soleno Therapeutics stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Soleno Therapeutics stock - Investing.com
Wall Street Recap: Will Soleno Therapeutics Inc. stock see insider buyingWeekly Investment Summary & Reliable Breakout Forecasts - Bộ Nội Vụ
Baird lowers Soleno Therapeutics stock price target to $107 on new starts trajectory - Investing.com
Soleno Therapeutics (NASDAQ:SLNO) Hits New 1-Year LowTime to Sell? - MarketBeat
Soleno Therapeutics stock hits 52-week low at 41.47 USD By Investing.com - Investing.com Nigeria
Soleno reports $189-191 million in 2025 VYKAT XR sales since launch - Investing.com Nigeria
SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc. - marketscreener.com
Soleno Therapeutics (NASDAQ:SLNO) Shares Gap UpTime to Buy? - MarketBeat
Soleno Therapeutics stock falls despite revenue beat as patient starts decline - Investing.com UK
Rally Mode: Will Soleno Therapeutics Inc stock deliver shareholder valueWeekly Investment Report & Technical Entry and Exit Tips - Bộ Nội Vụ
Soleno Therapeutics stock hits 52-week low at 41.47 USD - Investing.com
Soleno Therapeutics up on forecasting preliminary 2025 Vykat XR sales above estimates - TradingView — Track All Markets
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Potential Upside of 164% Captures Investor Attention - DirectorsTalk Interviews
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results - The Manila Times
SLNOSoleno Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Market Review: Why Soleno Therapeutics Inc stock is popular among millennialsWeekly Profit Report & Long-Term Capital Growth Strategies - moha.gov.vn
Peregrine Capital Management LLC Makes New Investment in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics, Inc.Common Stock (NQ: SLNO - FinancialContent
Soleno Therapeutics (SLNO) among stocks that will bounce back according to analysts - MSN
SLNO Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Bluefield Daily Telegraph
Soleno Therapeutics (NASDAQ:SLNO) Trading Down 4.2%What's Next? - MarketBeat
Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny - TechStock²
Will Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative? - Sahm
Soleno Therapeutics (SLNO) Among Stocks That Will Bounce Back According to Analysts - Insider Monkey
Why Soleno Therapeutics Inc. stock is popular among millennialsWeekly Investment Report & Safe Entry Momentum Stock Tips - ulpravda.ru
Assessing Soleno Therapeutics (SLNO) Valuation After JCEM VYKAT XR Data And FDA Approval - Yahoo Finance
Macro Review: Can Soleno Therapeutics Inc. stock hit record highs againJuly 2025 Short Interest & Expert Curated Trade Setups - ulpravda.ru
Can Soleno Therapeutics Inc. stock hit record highs again2025 Major Catalysts & Smart Investment Allocation Tips - ulpravda.ru
Bragar Eagel & Squire, P.C. Encourages Soleno, Avita, and Coty Investors to Contact the ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Encourages Soleno, Avita, and - GlobeNewswire
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
Will Soleno Therapeutics Inc. stock deliver strong dividend growthQuarterly Profit Review & Expert Curated Trade Setup Alerts - ulpravda.ru
What technical signals suggest for Soleno Therapeutics Inc. stockOil Prices & Weekly Setup with ROI Potential - ulpravda.ru
Does Soleno Therapeutics Inc. stock trade at a discount to peersWeekly Stock Report & Weekly High Return Opportunities - ulpravda.ru
Soleno Therapeutics announces entry into $100M accelerated share repurchase agreement - MSN
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo - The Globe and Mail
Is Soleno Therapeutics Inc. stock supported by strong fundamentalsEconomic Data Impact & Market-Leading Growth Rates - ulpravda.ru
Soleno Therapeutics (NASDAQ:SLNO) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
Do You Believe in the Growth Prospects of Soleno Therapeutics (SLNO)? - Finviz
Wells Fargo Reiterates a Buy Rating on Soleno Therapeutics (SLNO), Sets a PT of $123 - MSN
Soleno’s PWS treatment study results published in endocrinology journal By Investing.com - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.SLNO - Chartmill
A Look At Soleno Therapeutics (SLNO) Valuation After Pivotal VYKAT XR Study Publication And FDA Approval - Sahm
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):